Markets

Regeneron Pharmaceuticals Announces Data From Its Phase 3 OPTIMA Study Of Pasatru To Treat Fibrodysplasia Ossificans Progressiva Shows Efficacy In Stopping New Bone Growth; Trial Meets Primary Endpoint By Reducing 90% New Heterotopic Ossification Lesions

Oct 12, 2026 · 12:10 PM ET· updated 3h ago

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive 84-week results from the Phase 3 OPTIMA trial evaluating Pasatru™ (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP).

Why It Matters

Regeneron's new medicine Pasatru stopped most new bone growth in FOP patients. This means the drug works as hoped, which is important for people with this rare disease.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

REGN763.00

+16.46 (+2.20%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.